Method of preventing contrast-induced nephropathy

a technology of contrast-induced nephropathy and nephropathy, which is applied in the direction of biocide, drug composition, peptide/protein ingredients, etc., can solve the problems that contrast-induced morbidity has become a significant cause of hospital morbidity and mortality, and achieve the effect of preventing contrast-induced nephropathy

Inactive Publication Date: 2009-10-15
INOTECK PHARMA CORP
View PDF2 Cites 4 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0008]The present invention provides a method of preventing contrast-induced nephropathy including the step of admin

Problems solved by technology

Contrast-induced morbidity has become a significant cause of hospital morbidity and mortality with the increa

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Method of preventing contrast-induced nephropathy
  • Method of preventing contrast-induced nephropathy
  • Method of preventing contrast-induced nephropathy

Examples

Experimental program
Comparison scheme
Effect test

example 1

Effect of Metalloporphyrin A on CIN

[0195]The following groups of animals were prepared and studied as follows:

TREATMENTDailyStockDoseDosingGroupIndividualDrug / TestDoseSolution ofVolumeFrequencyNo.Animal No.MaterialLot #Route(mg / kg)Drug (mg / ml)(ml / animal)& duration1Diabetic ratsSalineNonei.p.NoneNoneNoneSaline 2X(n = 8)per day+i.v. SALINEfor 4 days(10 ml / kg)2Diabetic rats+Metallo-MC-i.p.10.250.252X per day(n = 8)porphyrin A016-91for 4 days+i.v. SALINE(10 ml / kg)3Diabetic ratsSalineNonei.p.None0.9% NaCl0.25Saline 2X(n = 8)per day+i.v.for 4 daysIOMEPROL(10 ml / kg)4Diabetic rats+Metallo-MC-i.p.0.030.250.252X per day(n = 8)porphyrin A016-91for 4 days+i.v.IOMEPROL(10 ml / kg)5Diabetic rats+Metallo-MC-i.p.0.10.250.252X per day(n = 8)porphyrin A016-91for 4 days+i.v.IOMEPROL(10 ml / kg)6Diabetic rats+Metallo-MC-i.p.0.30.250.252X per day(n = 8)porphyrin A016-91for 4 days+i.v.IOMEPROL(10 ml / kg)7Diabetic rats+Metallo-MC-i.p.10.250.252X per day(n = 8)porphyrin A016-91for 4 days+i.v.IOMEPROL(10 ml / kg)8...

example 2

Effects of N-Acetyl Cysteine (NAC) and Metalloporphyrin A on Contrast-Induced Nephropathy in Diabetic Rats

[0219]Male Wistar rats (150-200 g; Harlan Nossanr) were housed in a controlled environment and provided with standard rodent chow and water. Diabetes was induced after 2 hours of fasting. The animals received a single 60 mg / kg intravenous (i.v.) injection of streptozotocin (Sigma, St. Louis, Mo.) in 10 mM sodium citrate buffer, pH 4.5 (see figure). Control non-diabetic animals were fasted and received citrate buffer alone. After 24 hours, animals with blood glucose levels greater than 250 mg / dl were considered diabetic. The diabetic state was confirmed by evaluating the blood glucose levels. Ten days following the induction of diabetes rats were anesthetized with 90 mg / kg ketamine i.m. and 10 mg / kg xylazine i.m. and were treated with the contrast agent iomeprol (10 mL / kg injected via the lateral tail vein) or with 0.9% normal saline. The contrast agent used was the low osmolar n...

example 3

Effects of Super Oxide Dismutase Mimic (SODm) M40403 Alone and in Combination with N-Acetyl Cysteine (NAC) on Contrast-Induced Nephropathy in Diabetic Rats

[0226]Male Wistar rats (150-200 g; Harlan Nossanr) were housed in a controlled environment and provided with standard rodent chow and water. Diabetes was induced after 12 hours of fasting. The animals received a single 60 mg / kg intravenous (i.v.) injection of streptozotocin (Sigma, St. Louis, Mo.) in 10 mM sodium citrate buffer, pH 4.5 (see figure). Control non-diabetic animals were fasted and received citrate buffer alone. After 24 hours, animals with blood glucose levels greater than 250 mg / dl were considered diabetic. The diabetic state was confirmed by evaluating the blood glucose levels. Ten days following the induction of diabetes rats were anesthetized with 90 mg / kg ketamine i.m. and 10 mg / kg xylazine i.m. and were treated with the contrast agent iomeprol (10 mL / kg injected via the lateral tail vein) or with 0.9% normal sal...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Massaaaaaaaaaa
Massaaaaaaaaaa
Dimensionless propertyaaaaaaaaaa
Login to view more

Abstract

The present invention relates to methods of preventing contrast-induced nephropathy including the step of administering an effective amount of a compound (e.g., a peroxynitrite decomposition agent, a PARP inhibitor or a superoxide dismutase mimic) to a subject to be administered a contrast agent.

Description

RELATED APPLICATIONS[0001]This application claims priority to U.S. Provisional Patent Application No. 61 / 009,600, filed on Dec. 31, 2007, the entire contents of which are hereby incorporated by reference.BACKGROUND OF THE INVENTION[0002]Contrast-induced nephropathy (CIN) is generally recognized as acute renal failure occurring within 48 hours of exposure to intravascular contrast material, and where other causes of renal failure are not attributable. Its presence is generally determined when an increase in serum creatinine levels is exhibited in a subject who has been exposed to intravascular contrast material. Contrast-induced morbidity has become a significant cause of hospital morbidity and mortality with the increasing use of iodinated contrast media in diagnostic imaging and interventional procedures such as angiography. In 2003, over 80 million doses of iodinated intravascular contrast media were administered, corresponding to approximately 8 million liters according to Katzbe...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/44A61K31/444A61K31/409A61K31/555
CPCA61K31/555A61K31/473A61P13/12
Inventor FINK, MITCHELL P.
Owner INOTECK PHARMA CORP
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap